Skip to main content
. 2022 Sep 26;10(10):1612. doi: 10.3390/vaccines10101612

Table 4.

Emerging variants of SARS-CoV-2 and nAb, which are in the pre-clinical and clinical stage.

Sl. No. Name of the Variant Effective nAb against the SARS-CoV-2 Variants Reference
1. B.1.1.7 (Alpha) CD147 (Meplazumab), COVOX-222, COVOX-253, A23-58.1, MG1141A, Sotrovimab, Casirivimab + Imdevimab, Bamlanivimab + Etesevimab, Tixagevimab + Cilgavimeb [59,60,61]
2. B.1.351 (Beta) CD147 (Meplazumab), MG1141A, Casirivimab + Imdevimab, Sotrovimab, Tixagevimab + Cilgavimeb [59,60,62]
3. P.1 (Gamma) CD147 (Meplazumab), COVOX-222, COVOX-253, A23-58.1, Sotrovimab, Casirivimab + Imdevimab, MG1141A, Tixagevimab + Cilgavimeb [59,60,62]
4. B.1.617.2 (Delta) CD147 (Meplazumab), A23-58.1, Sotrovimab, Casirivimab + Imdevimab, Bamlanivimab + Etesevimab, Tixagevimab + Cilgavimeb [60,62,67]
5. B.1.1.529 (Omicron) Sotrovimab, Paxlovid, molnupiravir [73,74]